The patient impact of point-of-care vs. Laboratory placement of XpertW MTB/RIF

International Journal of Tuberculosis and Lung Disease

Volumn 19, Issue 7, 2015, Pages 811-816

  Hanrahan, C F ^a,g   Clouse, K ^b   Bassett, J ^c   Mutunga, L ^c   Selibas, K ^d   Stevens, W ^e,f   Scott, L ^f   Sanne, I ^d   Van Rie, A ^a  

^a IL   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c Witkoppen Health and Welfare Centre   (South Africa)

^d Clinical HIV Research Unit   (South Africa)

^e UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^f NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

^g JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Diagnostics; South Africa; Tuberculosis

Indexed keywords

TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; FEMALE; HEALTH SERVICE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LABORATORY DIAGNOSIS; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; OFFSITE LABORATORY PLACEMENT; POINT OF CARE TESTING; PRIORITY JOURNAL; PROSPECTIVE STUDY; SOUTH AFRICA; TIME TO TREATMENT; TUBERCULOSIS RAPID TEST; TURNAROUND TIME; CD4 LYMPHOCYTE COUNT; COMPLICATION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; LABORATORY; MICROBIOLOGY; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; POINT OF CARE SYSTEM; PRIMARY HEALTH CARE; PROPORTIONAL HAZARDS MODEL; SPUTUM; STATISTICS AND NUMERICAL DATA; TUBERCULOSIS, PULMONARY; UTILIZATION;

ADULT; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HUMANS; LABORATORIES; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; POINT-OF-CARE SYSTEMS; PRIMARY HEALTH CARE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; SOUTH AFRICA; SPUTUM; TIME-TO-TREATMENT; TUBERCULOSIS, PULMONARY;

EID: 84930798881     PISSN: 10273719     EISSN: 18157920     Source Type: Journal    
DOI: 10.5588/ijtld.15.0013     Document Type: Article

References (14)

1. Lin H H, Dowdy D, Dye C, Murray M, Cohen T. The impact of new tuberculosis diagnostics on transmission: why context matters. Bull World Health Organ 2012; 90: 739-747A.
2. Sun AY, Pai M, Salje H, Satyanarayana S, Deo S, Dowdy D W. Modeling the impact of alternative strategies for rapid molecular diagnosis of tuberculosis in southeast Asia. Am J Epidemiol 2013; 178: 1740-1749.
3. Steingart K R, Sohn H, Schiller I, et al. Xpertw MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev 2013; 1: CD009593.
4. Lawn S D, Nicol M P. Xpertw MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance. Future Microbiol 2011; 6: 1067-1082.
5. Clouse K, Page-Shipp L, Dansey H, et al. Implementation of Xpert MTB/RIF for routine point-of-care diagnosis of tuberculosis at the primary care level. S Afr Med J 2012; 102: 805-807.
6. Hanrahan C F, Selibas K, Deery C B, et al. Time to treatment and patient outcomes among TB suspects screened by a single point-of-care xpert MTB/RIF at a primary care clinic in Johannesburg, South Africa. PLOS ONE 2013; 8: e65421.
7. Theron G, Zijenah L, Chanda D, et al. Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: A multicentre, randomised, controlled trial. Lancet 2014; 383: 424-435.
8. National Health Laboratory Service. NPP Implementation of GeneXpert for TB testing. Johannesburg, South Africa: NHLS, 2013. http://www.nhls.ac.za/?page1/4genexpert-for-tb-testing&id1/469 Accessed March 2015.
9. World Health Organization. Scaling up antiretroviral therapy in resource-limited settings: Treatment guidelines for a public health approach. 2003 revision. Geneva, Switzerland: WHO, 2013. http://www.who.int/3by5/publications/documents/arv-guidelines/en/Accessed March 2015.
10. Lawn S D, Kerkhoff A D, Wood R. Location of Xpertw MTB/RIF in centralised laboratories in South Africa undermines potential impact. Int J Tuberc Lung Dis 2012; 16: 701; author reply 2.
11. Churchyard G. Effect of Xpert MTB/RIF on early mortality in adults with suspected TB: A pragmatic randomized trial. Conference on Retroviruses and Opportunistic Infections (CROI), Boston, MA, USA, 3-6 March 2014. [Oral Abstract 95].
12. National Health Laboratory Services. GeneXpert testing algorithm. Johannesburg, South Africa: NHLS, 2013. http://www.nhls.ac.za/assets/files/GeneXpert%20poster.pdf Accessed March 2015.
13. World Health Organization. Definitions and reporting framework for tuberculosis. 2013 revision. WHO/HTM/TB/2013.2. Geneva, Switzerland: WHO, 2013.
14. Theron G, Peter J, Dowdy D, Langley I, Squire S B, Dheda K. Do high rates of empirical treatment undermine the potential effect of new diagnostic tests for tuberculosis in high-burden settings? Lancet Infect Dis 2014; 14: 527-532.